Jazz Pharmaceuticals and Saniona Collaborate on Innovative Epilepsy Treatment with New Licensing Agreement Jazz Pharmaceuticals has secured exclusive rights to SAN2355, a next-gen epilepsy treatment. This collaboration promises groundbreaking advancements in neurological therapy.

Jazz Pharmaceuticals and Saniona Collaborate on Innovative Epilepsy Treatment with New Licensing Agreement #Ireland #Dublin #Jazz_Pharmaceuticals #SAN2355 #Saniona